Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients

•The PVAB regimen yielded a complete metabolic response rate of 77.5% as first-line therapy for older HL patients, with acceptable toxicity.•The 4-year cumulative risk of events was 35% for progression and relapse, 9% for death from lymphoma and 6% for nonlymphoma events.